Abstract: Acute Myocardial Infarction (AMI) represents a severe manifestation of the spectrum of Acute Coronary Syndrome (ACS). The incidence of AMI has attained alarming proportions in both the developed and developing countries. Our preliminary short-term study focuses on the clinical application of the biomarker C-Reactive Protein (CRP) in the laboratory diagnosis potential of AMI. Besides the conventional markers, CRP and other biochemical markers and their role in cardiovascular diseases, has become a subject of interest in recent times. In the present study we evaluated the CRP values using "Chromatest" kit latex-agglutination technique on the venous blood samples of a total of 40 patients of whom 20 were admitted with AMI and 20 healthy volunteers (control). Other disease conditions that could raise CRP values were considered and excluded in the controls. The results were tabulated and statistical analysis indicated that CRP has significant potential as a biochemical marker that could be concomitantly used along with other established markers. We report our evaluation of CRP levels on the day of AMI occurrence and after a period of 10 days. The results (p< 0.005) indicate that mean CRP value of AMI for the day of admission (D1) was 6.092 mg L ¹. The mean values for males and females exclusively with AMI on D1 were 6.406 and 5.779 mg L ¹, respectively. The mean value of CRP 10 days post infarct (D2) was 2.793 mg L ¹. The mean values of CRP exclusively for males and females with AMI on D2 were 2.495 and 2.393 mg L ¹, respectively. The mean value of CRP in control group on D1 was 0.834 mg L ¹. The mean values of CRP on D1 for males and females exclusively were 0.839 and 0.824 mg L ¹. The mean values of CRP on D2 exclusively for males and females were 0.84 and 0.828 mg L ¹, respectively. Our study clearly shows the higher values of CRP in patients with AMI in comparison to normal subjects. The high values clearly indicate the detrimental effects of inflammation and myocardial necrosis. Males have slightly higher CRP values than females in both the control and patients with AMI. The study warrants the need for further research in the potential of clinical application of CRP and accentuates the possibility of concomitant use of CRP with other biomarkers due to its reasonable efficacy and cost.